Estimating the short-term clinical and economic benefits of smoking cessation: do we have it right?
- PMID: 19527098
- DOI: 10.1586/erp.09.28
Estimating the short-term clinical and economic benefits of smoking cessation: do we have it right?
Abstract
Smoking cessation is cost effective from a long-term perspective, but less is known about its short-term cost-effectiveness. Short-term health benefits are clear for certain groups, such as cardiovascular patients, pregnant women and patients undergoing surgery. Smoking cessation reduces overall mortality, cardiovascular mortality and cancer-related mortality within 5 years of quitting, and, in some cases, the risks are reduced to the levels of never smokers. In this article, conducted from a USA policy perspective, we found some evidence of the clinical and economic benefits of smoking cessation in the short term, which could be incorporated into cost-effectiveness studies. Nonetheless, the policy and social welfare implications of a short-term focus must be carefully evaluated, considering the established favorable long-term cost-effectiveness of smoking cessation.
Similar articles
-
The costs of smoking and the cost effectiveness of smoking-cessation programs.J Public Health Policy. 1990 Summer;11(2):218-37. J Public Health Policy. 1990. PMID: 2114423 Review.
-
The health benefits of smoking cessation for adult smokers and for pregnant women in Taiwan.Tob Control. 2005 Jun;14 Suppl 1(Suppl 1):i56-61. doi: 10.1136/tc.2004.007997. Tob Control. 2005. PMID: 15923451 Free PMC article.
-
[Determining the possibility of collecting reliable data for use in decision making in health care on the example of cost-effectiveness analysis of methods used in smoking cessation].Przegl Lek. 2004;61(10):1180-3. Przegl Lek. 2004. PMID: 15794284 Polish.
-
The total lifetime health cost savings of smoking cessation to society.Eur J Public Health. 2005 Dec;15(6):601-6. doi: 10.1093/eurpub/cki024. Epub 2005 Jul 13. Eur J Public Health. 2005. PMID: 16014659
-
Modelling the health benefits of smoking cessation in Japan.Tob Control. 2009 Feb;18(1):10-7. doi: 10.1136/tc.2007.024620. Epub 2008 Aug 26. Tob Control. 2009. PMID: 18728096 Review.
Cited by
-
Pharmacoeconomic spotlight on varenicline as an aid to smoking cessation.CNS Drugs. 2010 Sep;24(9):797-800. doi: 10.2165/11204710-000000000-00000. CNS Drugs. 2010. PMID: 20806990 Review.
-
Maximizing benefits for effective cancer survivorship programming: defining a dissemination and implementation plan.Oncologist. 2011;16(8):1189-96. doi: 10.1634/theoncologist.2011-0054. Epub 2011 Jul 17. Oncologist. 2011. PMID: 21765196 Free PMC article.
-
Budgetary impact analysis on funding smoking-cessation drugs in patients with COPD in Spain.Int J Chron Obstruct Pulmon Dis. 2015 Sep 24;10:2027-36. doi: 10.2147/COPD.S87597. eCollection 2015. Int J Chron Obstruct Pulmon Dis. 2015. PMID: 26451100 Free PMC article.
-
Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.Pharmacoeconomics. 2010;28(3):231-54. doi: 10.2165/11204380-000000000-00000. Pharmacoeconomics. 2010. PMID: 20108995 Review.
-
Short-term effects of national smoking cessation service on smoking-related disease prevalence and healthcare costs: Experience from the National Health Insurance Service Smoking Cessation Intervention Program in Korea.Tob Induc Dis. 2023 Aug 24;21:107. doi: 10.18332/tid/169654. eCollection 2023. Tob Induc Dis. 2023. PMID: 37637229 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical